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Abstract
New blood vessel formation (angiogenesis) is not only essential for the growth of solid tumors but there is also 
emerging evidence that progression of hematological malignancies like multiple myeloma, acute leukemias, and 
myeloproliferative neoplasms, also depends on new blood vessel formation. Anti-angiogenic strategies have become 
an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting angiogenesis-related 
pathways like monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulatory drugs, and proteasome 
inhibitors have been entered clinical trials or have been already approved for the treatment of hematological 
malignancies as well and in some instances these pathways have emerged as promising therapeutic targets. This 
review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological 
malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis.
Introduction
The hypothesis of tumor angiogenesis in malignancies
was raised by Judah Folkman: To grow over a certain size
of a few millimetres in diameter solid tumors need blood
supply from surrounding vessel [1]. Up to 2-3 mm3 solid
tumors can grow without blood vessel supply. Nutrition
and oxygen is provided via diffusion from the surround-
ing tissue. Above this size, diffusion becomes insufficient
due to the negative surface/volume ratio. Based on a bal-
ance between angiogenic and anti-angiogenic growth fac-
tors, a tumor of this size can stay dormant for a very long
time period until the so-called angiogenic switch occurs
[2]. Tumor blood vessels are generated by various mecha-
nisms, such as expansion of the host vascular network by
budding of endothelial sprouts (sprouting angiogenesis),
cooption of the existing vascular network, remodeling
and expansion of vessels by the insertion of interstitial tis-
sue columns into the lumen of preexisting vessels (intus-
susceptive angiogenesis) and homing of endothelial cell
precursors (EPC; CEP) from the bone marrow or periph-
eral blood into the endothelial lining of neovessels (vas-
culogenesis) [3].
Tight control of angiogenesis is maintained by a bal-
ance of endogenous anti-angiogenic and pro-angiogenic
factors [4]. VEGF has a key, rate-limiting role in promot-
ing tumor angiogenesis and exerts its effects by binding
to one of three tyrosine kinase receptors: VEGF receptor-
1 (VEGFR-1; fms-like tyrosine kinase-1, Flt-1), VEGFR-2
(human kinase domain region, KDR/murine fetal liver
kinase-1, Flk-1) and VEGFR-3 (Flt-4). VEGFR-1 (ligands
include VEGF-A, -B and placental growth factor [PIGF])
and VEGFR-2 (ligands include VEGF-A, -C and -D) are
predominantly expressed on vascular endothelial cells,
and activation of VEGFR-2 appears to be both, necessary
and sufficient, to mediate VEGF-dependent angiogenesis
and induction of vascular permeability [4,5]. Both recep-
tor tyrosine kinases are expressed in all adult endothelial
cells, except for the brain endothelial cells. VEGFR-1 is
also expressed on hematopoietic stem cells, vascular
smooth muscle cells, monocytes, and leukemic cells [6,7],
while VEGFR-2 is expressed on endothelial progenitor
cells and megakaryocytes [8,9]. VEGFR-3, largely
restricted to lymphatic endothelial cells, binds the VEGF
homologues VEGF-C and VEGF-D and may play an
important role in the regulation of lymphangiogenesis.
Thus, VEGF and VEGFR represent significant anti-can-
cer therapy targets, which elegantly bypass potential
tumor-related treatment barriers [4].
A further important pathway in angiogenesis is the
recently identified Delta-Notch pathway, and particularly
the ligand Delta-like 4 (Dll4), was identified as a new tar-
get in tumor angiogenesis [10]. Dll4 is highly expressed by
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vascular endothelial cells and induced by VEGF [11]. It
interacts with Notch cell surface receptors to act as a neg-
ative feedback inhibitor downstream of VEGF signaling
to restrain the sprouting and branching of new blood ves-
sels [10,12]. Inhibition of Dll4-Notch signaling induces an
increase in vessel density but these blood vessels are
abnormal and not perfused [13]. Therefore intratumour
hypoxia is increased and leads to induction of transcrip-
tion of proangiogenic genes regulated by Hypoxia induc-
ible factor-1 (HIF-1) [10,14]. Disruption of Dll4 signaling
by overexpression or inhibition of Dll4 may impair angio-
genesis and blockade of Dll4-Notch signaling results in an
increased density of nonfunctional vasculature and is
associated with a reduction in the growth of human
tumor xenografts [13,14]. Further, certain xenografts that
are resistant to anti-VEGF therapy are reported to be sen-
sitive to anti-Dll4 and combination treatment with anti-
VEGF and anti-Dll4 has additive inhibitory effects on
tumor growth [13-15].
This review summarizes the role of pathological angio-
genesis in hematological malignancies focusing on multi-
ple myelomas (MM), acute leukemias, and
myeloproliferative neoplasms (MPN) and its therapeutic
intervention with novel agents within clinical trials or
already approved.
Pathophysiology of angiogenesis in hematological 
malignancies
Many studies suggest a role for angiogenesis not only in
the pathogenesis of solid tumors but also in hematologi-
cal malignancies like acute and chronic leukemia, lym-
phoma, myelodysplastic syndromes, myeloproliferative
neoplasms, and multiple myeloma [16-21]. We and others
reported an increased microvessel density and VEGF
expression in the bone marrow of patients with myelo-
proliferative neoplasms and lymphoma [17,20]. Thereby,
the extent of angiogenesis in the bone marrow often cor-
related with disease burden, progonosis, and treatment
outcome [22,23]. In the neoplastic bone marrow there is
an imbalance of the cells, cytokines and growth factors
maintaining physiological angiogenesis in the normal
bone marrow. The bone marrow tumor cells upregulates
several factors, including interleukin-6, granulocyte-mac-
rophage colony-stimulating factor and VEGF, have auto-
crine and paracrine effects acting on multiple cell types,
thereby stimulating angiogenesis and leading to increased
vascularity [7,24]. The role for VEGF in hematogical
malignancies has been extensively studied since its isola-
tion from the leukemia cell line HL- 60 in 1989 [25].
Apparently, this growth factor is expressed in many other
leukemic cell lines [7,26] and a subset of leukemic cells
also expresses VEGFR-2 which allows VEGF to act as
autocrine growth factor in leukemia [26,27]. In addition
to that, isolated blast cells from leukemia patients also
produce VEGF [26] and the cellular level of VEGF in
acute myeloid leukemia (AML) patients has been identi-
fied as independent prognostic risk factor [28]. VEGF
from leukemic blasts contributes to disease progression,
either as positive regulator for proliferation and apoptosis
protection for the blast itself or by activating the sur-
rounding stroma cells with subsequent induction of bone
marrow angiogenesis.
Regarding the Notch pathway, Notch signals are onco-
genic in hematogical malignancies in many cellular con-
texts [29]. Activating Notch-mutations have been shown
to be present in at least 50% of human T-cell acute lym-
phoblastic leukaemia (T-ALL) cases and have been
proved to play a unifying role in the pathogenesis of T-
ALL [30]. An important role of Notch has been proposed
i n  c e l l  s u r v i v a l  i n  s e v e r a l  B - c e l l  m a l i g n a n c i e s  s u c h  a s
Hodgkin's disease [31,32] and in two B-cell non-Hodgkin
lymphoma entities, chronic lymphocytic leukaemia
(CLL) [33-35] and in MM [36,37].
Multiple myeloma
MM was the first hematological malignancy, in which
increased angiogenesis rate was detected [21,38]. MM is
characterized by proliferation of malignant plasma cells
that accumulate in the bone marrow and often produce a
monoclonal immunoglobulin. New vessel formation in
the bone marrow seems to play an important role in the
pathogenesis of MM [39,40]. Increased bone marrow
microvessel density (MVD) in patients with MM appears
to be also an important prognostic factor [41]. Malignant
plasma cells can secrete various cytokines, including
VEGF, basic fibroblast growth factor (bFGF), and hepato-
cyte growth factor (HGF), all known for their pro-angio-
genic activity [42]. It has been shown that MM cells are
capable of secreting VEGF in response to Interleukin-6
(IL-6) stimulation; in response to that VEGF stimulation
microvascular endothelial cells and bone marrow stromal
cells secrete in turn IL-6, a potent growth factor for
malignant plasma cells, thus closing a paracrine loop [43].
Specifically, increased microvessel density (MVD) in the
BM of MM patients has been correlated with disease pro-
gression and poor prognosis [21,23]. Moreover, VEGF
also exerts direct effects on MM cell migration, prolifera-
tion, survival, and drug resistance. VEGF triggered effects
in MM cells are predominantly mediated via VEGFR 1
and in endothelial cells, predominantly via VEGF R2 [44].
Rajkumar et al. showed a gradual increase of bone mar-
row angiogenesis along the disease spectrum from mono-
clonal gammopathy of undetermined significance
(MGUS) to smoldering MM, newly diagnosed MM and
relapsed MM [45], though the expression levels of VEGF,
bFGF, and their receptors were similar among MGUS,Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
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smoldering MM, and newly diagnosed MM [46], rising
the hypothesis that MVD increase in plasma cell neopla-
sias could be rather a function of chronology.
Acute leukemias
The first demonstration that leukemia progression might
be accompanied by an increase of bone marrow vascular-
ization was provided by Judah Folkman's group [47]. In
their studies, it was demonstrated that the bone marrow
of acute lymphoblastic leukemia (ALL) patients had
increased blood vessel content, compared to normal
counterparts. Moreover, it was also shown that urine and
peripheral blood samples from ALL patients contained
elevated levels of pro-angiogenic growth factors, namely
bFGF and VEGF, which correlated with the increase of
bone marrow angiogenesis [48]. The existence of an
"angiogenesis switch", first proposed for solid tumors
[49], was therefore suggested to apply to hematological
malignancies as well. "Angiogenesis switch" in leukemia is
documented by increased bone marrow MVD, increased
expression of HIF-1, multiple pro-angiogenic factors
(VEGF, bFGF, angiopoietin-2), soluble VEGFR, and
decreased expression of endogenous angiogenesis inhibi-
tors, such as thrombospondin-1 [50,51].
In a recent study by Norén-Nyström et al. [52] MVD,
analyzed on 185 bone marrow biopsies, was higher in T-
ALL compared to B-ALL. In the B-ALL group, cases with
t(12;21) were characterized by a low MVD, while patients
with hyperdiploid leukemia showed a high MVD. Simi-
larly, in previously untreated acute myeloid leukemia
(AML), increased levels of plasma VEGF correlate with
reduced survival and lower remission rates [53]. In addi-
tion to that, isolated blast cells from leukemia patients
also produce VEGF and the cellular level of VEGF in
AML patients has been identified as independent prog-
nostic risk factor [28]. In a reccent study [54] dynamic
contrast-enhanced magnetic resonance imaging (DCE-
MRI) was used as a non-invasive technique to measure
bone marrow angiogenesis in AML. DCE-MRI was per-
formed beforte treatment and on day 7 after induction
chemotherapy. Thereby, bone marrow angiogenesis with
remission, rate overall and disease-free survival.
Myeloproliferative neoplasms
The available data on angiogenesis and expression of
VEGF and its receptors in the bone marrow of patients
with  BCR-ABL1-negative myeloproliferative neoplasms
(MPN) suggest that MVD is increased, especially in pri-
mary myelofibrosis (PMF), and that increased angiogene-
sis might inversely correlate with survival [55-58]. In a
recent study, we found a significantly increased MVD and
VEGF expression in MPN compared to controls espe-
cially in cases with high JAK2-V617F mutant allele bur-
dens [17]. The identification of an acquired somatic
mutation in the JAK2 gene, resulting in a valine to pheny-
lalanine substitution at position 617 (JAK2-V617F), has
provided new insights into the pathogenesis of BCR-
ABL1-negative MPN, being present in most patients with
polycythaemia vera (PV) and in about 50% of patients
with essential thrombocythemia (ET) and PMF [59,60].
In another study by Alonci et al. in patients with MPN,
serum levels of VEGF and VEGFR-2 was examined. In
M P N ,  V E G F  l e v e l s  w e r e  h i g h e r  c o m p a r e d  t o  c o n t r o l s,
wheresas VEGFR-2 levels was reduced in ET but not in
PV and PMF [61].
Anti-angiogenic therapies in hematological 
malignancies
Anti-angiogenic therapies are mostly based on inhibiting
the binding of VEGF to VEGFR by neutralizing antibod-
ies to the ligand or to the receptor, soluble receptors,
small molecule inhibitors or are directed against the
tyrosine kinase activity of the VEGF receptors (Figure 1).
The first anti-angiogenic agent to be approved in solid
tumors was bevacizumab (Avastin™, Genentech), a
humanized anti-VEGF monoclonal antibody. Adminis-
tration of bevacizumab, in combination with cytotoxic
chemotherapy, conferred benefits to patients with meta-
static colorectal cancer, non-squamous, non-small cell
lung cancer and metastatic breast cancer [62-64]. Addi-
tionally, two small-molecule inhibitors targeting VEGFRs
and other kinases, sorafenib (Nexavar™, Bayer and Onyx
pharmaceuticals) and sunitinib (Sutent™, Pfizer), have
been approved based on their efficacy in treating renal
cell- and hepatocellular carcinoma [65,66]. A growing list
of anti-angiogenics is now available, either in various
stages of clinical development or as components of stan-
dard clinical regimens. The major classes of anti-angio-
genic therapy include: (1) direct anti-VEGF acting
molecules (anti-VEGF antibodies, VEGF-antisense nucle-
otides); (2) immunomodulatory drugs (IMIDs) with anti-
angiogenic properties; (3) receptor tyrosine kinase
inhibitors, targeting VEGFR signaling as well as receptors
of other (pro-angiogenic) factors; (4) anti-endothelial
approach of metronomic therapy and (5) other new com-
pounds, targeting signaling downstream to pro-angio-
g e n i c  g r o w t h  f a c t o r s ,  s u c h  a s  m a m m a l i a n  t a r g e t  o f
rapamycin (mTOR) inhibitors, histone deacetylases'
(HDAC) inhibitors and proteasome inhibitors.
In our review, we will focus on several molecules inter-
fering with the VEGF/VEGFR system, which already have
been approved or are currently evaluated in clinical trials
for treatment of hematological malignancies (Table 1).
Anti-VEGF monoclonal antibodies
Bevacizumab
The humanized monoclonal anti-VEGF antibody bevaci-
zumab (Avastin®) is the first drug targeting VEGF and isMedinger and Mross Journal of Angiogenesis Research 2010, 2:10
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officially approved in combination with chemotherapy.
Bevacizumab is a humanized murine anti-human VEGF
monoclonal IgG1  antibody that blocks the binding of
human VEGF to its receptors, thereby disrupting also
autocrine and paracrine survival mechanisms mediated
by VEGFR-1 and VEGFR-2 [67]. Bevacizumab was
approved for advanced non-small cell lung cancer
(NSCLC), breast cancer, and colorectal cancer. In
patients with refractory AML (n = 9) bevacizumab
r e s u l t ed  i n  r ed u c t i o n  o f  V E G F  e x p r e s s i o n  i n  t h e  bo n e
marrow but without a clinical response [68]. Bevaci-
zumab-associated side effects are generally mild to mod-
erate in severity, although there are specific, uncommon
events that are more severe and potentially lifethreaten-
ing. The most commonly observed adverse events are
hypertension, proteinuria, bleeding and thrombosis,
which are generally mild to moderate and manageable
[68]. In a phase II clinical trial by Karp et al. bevacizumab
was administered after chemotherapy to adults with
refractory or relapsed AML [69]. Bevacizumab 10 mg/kg
was administered on day 8 after cytarabine beginning day
1 and mitoxantrone beginning day 4. Forty-eight adults
received induction therapy. Overall response was 23 of 48
(48%), with complete response (CR) in 16 (33%). Eighteen
patients (14 CR and 4 partial responses) underwent one
consolidation cycle and 5 (3 CR and 2 partial responses)
underwent allogeneic transplant. Median overall and dis-
ease-free survivals for CR patients were 16.2 months
(64%, 1 year) and 7 months (35%, 1 year), respectively. As
biomarkers, the microvessel density in bone marrow
biopsies, serum VEGF levels and the expression of the
VEGFR-1 FLT1 by AML marrow blasts were determined.
The expression of FLT-1 in pretreatment AML marrow
cells was higher compared to normal bone marrow. Bone
marrow samples demonstrated marked MVD decrease
after bevacizumab. VEGF was detected in pretreatment
serum in 67% of patients tested, increased by day 8 in
52%, and decreased in 93% (67% undetectable) 2 h after
bevacizumab. Currently, bevacizumab is evaluated as
treatment option for newly diagnosed AML in combina-
tion with cytarabine and idarubicin in a phase II study.
Anticalins©
The anticalins represent a novel class of human binding
proteins. PRS-050 is an anticalin with extended serum
half-life due to pegylation. This anticalin targets VEGF
and exhibits favourable binding und functional in vitro
activity profile in direct comparison to the currently
approved VEGF antagonists. A strong enhanced vascular
permeability was demonstrated. The wordwide "first trial
in man" is running since May 2010 and first results will be
Figure 1 Therapeutic strategies to target the VEGF/VEGF receptor system. VEGF, vascular endothelial growth factor.Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
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expected in 2011. The potential use will be similar to Bev-
acizumab. Its usefulness in malignant hematological dis-
orders has to be explored after the phase I study.
Receptor tyrosine kinase inhibitors
Small tyrosine kinase inhibitors that target VEGFR are a
further important class of anti-angiogenic drugs. Their
efficacy in hematological malignancies, especially in
AML, might be attributable to inhibition of a lot of path-
ways, especially such related to c-kit and Flt3.
SU5416 (Semaxinib) is a small molecule inhibitor of
VEGFR-1 and 2, c-kit and Flt3 [70-72]. In a phase II study,
42 patients with advanced AML were treated [70]. 7
patients achieved a partial response (reduction of blasts
by at least 50%), with one complete morphological
response lasting 2 months. Treatment was generally well
tolerated. Most study drug-related adverse events were
m i l d  t o  m o d e r a t e  i n  s e v e r i t y  a n d  t h e  m o s t  f r e q u e n t l y
reported adverse events were nausea, bone/muscoloskel-
etal pain, headache, insomnia, and vomiting. As biomark-
ers, VEGF RNA expression by leukemic blasts, bone
marrow MVD, and the expression of the target receptors
c-kit, Flt3, VEGFR-1, and VEGFR-2 prior to therapy was
determined. Patients with AML blasts expressing high
levels of VEGF mRNA by quantitative polymerase chain
reaction (PCR) had a significantly higher response rate
and reduction of bone marrow MVD than patients with
Table 1: Selection of clinical trials and approved anti-angiogenic therapies in hematological malignancies
Drug Target Study entities Approved for
Receptor tyrosine kinase 
inhibitors
PTK787/ZK 222584 (Vatalanib®) VEGFR1-3, PDGFRβ, c-Kit AML, PMF, MDS, CML, DLBCL, MM
SU5416
(Semaxinib)
VEGFR1-2, c-kit, Flt3 AML, MDS, MM, MPN
Sorafenib (Nexavar®) VEGFR2-3, B-Raf, Faf-1, PDGFRβ AML, ALL, MDS, CML, CLL, NHL, MM Advanced renal cell carcinoma, HCC
Sunitinib (Sutent®) VEGFR1-3, PDGFRα+β, c-kit, Flt3 AML, MDS, CLL, Myeloma, NHL Advanced renal cell carcinoma, GIST
PKC-412 (Midostaurin) VEGFR2, PKC, PDGFR, Flt3, c-Kit AML
Cediranib (Recentin®) VEGFR1-3, PDGFRβ, c-Kit AML, MDS, CLL
Proteasome inhibitors
Bortezomib (Velcade®) 26S proteasome, NF-κB AML, ALL, MDS, CML, NHL, MCL MM, MCL
Anti-VEGF strategies
Bevacizumab (Avastin®) VEGF-A AML, MDS, CLL, CML, NHL, MM Metastatic colorectal cancer, NSCLC, 
breast cancer
Immunomodulatory drugs
Thalidomide bFGF, VEGF, IL-6 AML, MDS, MPN, CLL, NHL, MM MM
Lenalidomide (Revlimid®) bFGF, VEGF, IL-6 AML, MDS, CLL, NHL MM, 5q- MDS
AML, acute myeloid leukemia; bFGF, basic fibroblast growth factor; DLBCL, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; 
CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumors; HCC, hepatocellular carcinoma; IL-6, Interleukin-6; NHL, non-Hodgkin 
lymphoma; NSCLC, non-small cell lung cancer; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, 
myeloproliferative neoplasm; PMF, primary myelofibrosis; VEGF, vascular endothelial growth factor.Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
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low VEGF expression consistent with the anti-angiogenic
effects of SU5416. Patients with a high c-kit expression
had a lower response.
Vatalanib (formerly PTK787/ZK 222584) is an oral pro-
tein kinase inhibitor (PTK) acting as angiogenesis inhibi-
tor that is active against VEGFR and PDGFR tyrosine
kinases, thereby offering a novel approach to inhibiting
tumor growth [73]. It interferes with the ATP binding
sites of VEGFR. In a phase I study by us, vatalanib was
well tolerated and showed clinical activity in a variety of
solid tumors [74]. It is active in MM by primarily reduc-
ing the number of tumor microvessels, accompanied by
dilation of the remaining vessels [75,76]. Ongoing studies
evaluate the efficacy of valatinib in combination with
imatinib in a phase I/II trial for patients with AML, PMF,
and blast phase of chronic myelogenous leukemia. Vata-
lanib was studied in a phase I clinical trial alone or in
combination with cytosine-arabinoside and daunorubicin
in patients with myelodysplastic syndromes (MDS) and
AML [77]. Sixty-three patients received vatalanib at
doses of 500-1000 mg/bid orally. At 1000 mg/bid, dose-
limiting toxicities such as lethargy, hypertension, nausea,
emesis and anorexia were observed. CR was observed in 5
of 17 evaluable AML patients treated with vatalanib com-
bined with chemotherapy. The authors concluded that
vatalanib is generally well tolerated and can be given in
combination with chemotherapy in patients with MDS
and AML. In a recently study by Barbarroja et al. [78]
vatalanib was examined in combination with idarubicin
in 4 AML cell lines and 7 AML patients samples. Vata-
lanib decreased VEGF levels and VEGFR phosphoryla-
tion in AML cells, which showed FLT3 internal tandem
reduplications/mutations (ITD), raising the question of
the actual targeted tyrosine kinase (VEGFR or flt3). In
another study, vatalanib was given to 29 patients with
PMF at doses of 500 or 750 mg/bid. One patient (3%)
achieved CR and 5 (17%) clinical improvement. All
together, vatalanib had modest activity in patients with
PMF [79].
Cediranib (AZD2171, Recentin®) is a potent inhibitor of
both VEGFR-1 and VEGFR-2; it also has activity against
c-kit, PDGFR-β, and VEGFR-3 at nanomolar concentra-
tions [80]. In our study, cediranib was well tolerated up to
45 mg/d in patients with a broad range of solid tumors
[81]. The most common toxicities included diarrhea, dys-
phonia, and hypertension. In a phase I study with
cediranib in 35 AML patients the most common adverse
events were diarrhea, hypertension and fatigue. Six
patients experienced an objective response (3 each at 20
and 30 mg). Dose and time-dependent reductions of solu-
ble VEGFR-2 were observed, and there was a correlation
between cediranib exposure and plasma VEGF levels
[82].
Immunomodulatory drugs (IMiDs)
Thalidomide was originally introduced as sedative and
withdrawn in the 1960's due to deleterious side effects.
Recently, there is increasing evidence for the efficacy of
thalidomide in cancer therapy. Multiple myeloma is one
of the first clinical entities for which this could be demon-
strated [83,84]. The surprising effects of thalidomide have
led to the development of a series of IMiDs with even
higher anti-angiogenic potency (Figure 2). It has has been
shown that thalidomide has important immunomodula-
tory effects by decreasing TNF-α synthesis and slectively
modulating T cell subsets shifting the T cell population
towards T helpers [85]. The interest on thalidomide as an
anti-neoplastic agent rose after demonstration of its anti-
angiogenic activity in a rabbit model of corneal neovascu-
larization that was induced in response to bFGF [86].
Thalidomide and the newer immunomodulatory drugs
(IMiDs) (e.g. lenalidomide) have been shown to signifi-
cantly decrease the expression of the pro-angiogenic fac-
tors VEGF and Interleukin-6 (IL-6) in MM [87]. The
newer IMiDs were found to be 2-3 times more potent
compared to thalidomide concerning anti-angiogenic
activity in various in vivo assays [88]. The anti-angiogenic
activity of IMiDs has been shown to be independent of
their immunomodulatory effects [89].
Thalidomide monotherapy in a phase II trial, in which
84 patients with relapsed and refractory MM received
doses ranging from 200 to 800 mg/d, resulted in an over-
all response rate of 32%. The 2-year event-free survival
and overall survival were 20 and 48%, respectively [83,84].
In combination with dexamethasone the response rate
was 63% compared to 41% with dexamethasone alone in
patients with newly diagnosed MM [90]. Thalidomide
was approved for the treatment of newly diagnosed MM.
In patients with AML, thalidomide was examined as
mono- and combination therapy. In a phase II study by
Thomas et al. [91] thalidomide was analyzed in patients
with relapsed or refractory AML previously treated with
cytarabine-containing regimens. A total of 16 patients
were treated with oral thalidomide 200-800 mg/d. Over-
all, one patient (6%) achieved CR lasting for 36 months,
and two patients had a transient reduction in marrow
b l as ts  f r o m  8 %  a n d  7 %  t o  l e s s  t h a n  5 %  i n  bo t h  cas e s.
There was no correlation between reduction of angiogen-
esis markers' levels and response. In a phase I/II trial by
Steins et al. [92] a dose-escalating trial was performed to
study the safety and efficacy of thalidomide in 20 AML
patients. Thirteen patients were assessable for both toxic-
ity and response, tolerating a maximum dose of 200-400
mg/d for at least 1 month. Overall, adverse events were
fatigue, constipation, rash, and neuropathy (grade 1 to 2
in most patients). In 4 patients, a partial response,
defined as reduction of at least 50% of the blast cell infil-Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
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tration in the bone marrow accompanied by increases of
platelet counts and hemoglobin values, was observed. In
parallel, MVD significantly decreased in these 5 patients
during treatment with thalidomide. A combination ther-
apy of thalidomide and 5-azacytidine, a hypomethylating
drug, was examined in 40 patients with MDS and AML
[93]. A hematological improvement was observed in 15 of
36 patients (42%), stable disease was observed in 5 of 36
patients (14%), and 10 of 36 patients (28%) had disease
progression. Six patients had CR.
In a phase II study with 44 PMF patients thalidomide
was examined as monotherapy [94]. Seventeen of 41 eval-
uable patients (41%) receiving treatment for at least 15
days showed a response. A complette remission (without
r e v e r s a l  o f  b o n e  m a r r o w  f i b r o s i s )  w a s  a c h i e v e d  i n  4
patients (10%), a partial response was achieved in 4
patients (10%), and hematological improvements of ane-
mia, thrombopenia, and/or splenomegaly were observed
in 9 patients (21%).
Lenalidomide, a synthetic compound derived by modi-
fying the chemical structure of thalidomide, has also
immunomodulatory and anti-angiogenic properties,
while showing lower adverse effects rates [95]. In patients
with previously treated relapsed/refractory MM, the
combination of lenalidomide with dexamethasone
increased the response rate from 22.5% to 59.2% com-
pared to dexamethasone alone [96,97]. In 2 phase III tri-
als lenalidomide in combination with dexamethasone, it
showed remarkable response rates and better toxicity
profile than thalidomide [96,97]. Lenalidomide was
approved in combination with dexamethasone for the
second-line treatment of MM.
In phase II studies with lenalidomide monotherapy in
patients with symptomatic PMF, the overall response
rates were 22% for anemia, 33% for splenomegaly, and
50% for thrombocytopenia [98]. In a combination study
of lenalidomide with prednisone, 40 patients with PMF
were included [99]. Responses were recorded in 12
Figure 2 Modes of action of IMiDs. IL-6, interleukin-6; IMiDs, immunomodulatory drugs; NK cells, Natural killer cells; Th1 cells, T helper 1 cells; TNFα, 
tumor necrosis factor alpha; Treg, regulatory T cells; VEGF, vascular endothelial growth factor.Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
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patients (30%) and are ongoing in 10 (25%). The median
time to response was 12 weeks. Three patients (7.5%) had
partial response and nine patients (22.5%) had clinical
improvement durable for a median of 18 months. Overall
response rates were 30% for anemia and 42% for spleno-
megaly. Interestingly, all eight JAK2-V617F-positive
responders experienced a reduction of the baseline
mutant allele burden as well.
Proteasome inhibitors
Bortezomib (Velcade®), a boronic acid dipeptide, is a
selective, but reversible proteasome inhibitor [100]. It has
been approved for clinical use in humans, in particular
for treatment MM and mantle cell lymphoma. Beside its
direct anti-tumor effects, anti-angiogenic actions of bort-
ezomib have recently been described in vitro and in vivo
[100]. In a study by Roccaro et al. [101] the effect of bort-
ezomib on the angiogenic phenotype of MM patient-
derived endothelial cells was examined. Bortezomib
inhibited the proliferation of endothelial cells and angio-
geneis in a dose-dependent manner.
In a phase III study, patients with MM progressing after
at least one prior therapy, were randomized to receive
single-agent bortezomib or high-dose dexamethasone
[102]. Alltogether 669 patients were included. Time to
progression was significantly prolonged in the borte-
zomib treatment arm (median, 6.2 months) compared
with the dexamethasone arm (median, 3.5 months). Anal-
ysis of overall survival done on the interim database (with
20% of events) showed the superiority of bortezomib for
patients. The response rate (complete plus partial
response) with bortezomib was also superior to dexame-
thasone (38% versus 18%). Adverse events on the borte-
zomib arm were similar to those previously observed in
phase II studies; some notable adverse events being
asthenia, peripheral neuropathy, thrombocytopenia, and
neutropenia. In another phase III study, bortezomib, mel-
phalan, and prednisone (VMP) was examined versus mel-
phalan and prednisone (MP) in previously untreated
symptomatic MM patients ineligible for high-dose ther-
apy [103]. VMP resulted in a 35% reduced risk of death
compared to MP and prolonged overalls survival. In a
phase I/II study by Richardson et al. [104] the combina-
tion lenalidomide, bortezomib, and dexamethasone was
evaluated in front-line myeloma. The partial response
rate was 100% in both the phase II population and overall,
with 74% and 67% each achieving very good partial
response or better. The combination lenalidomide, borte-
zomib, and dexamethasone demonstrated favorable toler-
ability and was highly effective in the treatment of newly
diagnosed myeloma. In a phase I study, bortezomib was
added to induction chemotherapy in patients with AML
[105]. The combination of bortezomib, idarubicin, and
cytarabine showed a good safety profile. The recom-
mended dose of bortezomib for phase II studies with ida-
rubicin and cytarabine was 1.5 mg/m2. Overall, 19
patients (61%) achieved complete remission (CR) and
three had CR with incomplete platelet recovery.
Conclusions and future directions
A n g i o g e n i c  a n d  e s p e c i a l l y  V E G F / V E G F R  p a t h w a y s  a r e
involved in the pathophysiology of hematological malig-
nancies including multiple myeloma, acute and chronic
leukemias, MPN and lymphomas. Although VEGF/
VEGFR-related pathways seems to be the most relevant
regulators of neoangiogenesis, vasculogenesis and
recruitment of endothelial progenitor cells in such
instances, but other pathways are important too. Further,
VEGF/VEGFR interactions can stimulate proliferation,
migration and survival of leukemia/lymphoma cells by
autocrinous and paracrinous loops. Novel agents, target-
ing VEGF, its receptors, and other angiogenic pathways,
are in various stages of clinical development and investi-
gation in hematological malignancies. As we know from
the the treatment of solid tumors, combination therapies
of different anti-angiogenic molecules with chemother-
apy or irradiation increases treatment efficacy. Especially,
as blocking VEGF activity has been shown to sensitize the
vasculature and improve the delivery of cytotoxic drugs
to tumor and endothelial cells. However, not all patients
treated with anti-angiogenic therapies benefit from this
kind of therapy and in most cases, the effect is transient.
Therefore, there is an urgent need for biomarkers to iden-
tify patients likely to benefit from anti-angiogenic treat-
ments, to select the optimal dose to minimize side effects,
and to understand the mechanisms of resistance. Preclin-
ical models suggest multiple mechanisms involved in
acquired or primary resistance against anti-angiogenic
therapies. Finally, also these "targeted therapies" has side
effects profiles which must be considered carefully.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MM and KM selected publications for the review, drafted manuscript. Both
authors read and approved the final manuscript.
Author Details
1Department of Hematology, University Hospital Basel, Petersgraben 4, 4031 
Basel, Switzerland and 2Department of Medical Oncology, Tumor Biology 
Center at the Albert-Ludwigs-University, Breisacherstrasse 117, D-79106 
Freiburg, Germany
References
1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other 
disease.  Nat Med 1995, 1:27-31.
2. Folkman J: Tumor angiogenesis: therapeutic implications.  N Engl J Med 
1971, 285:1182-1186.
3. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig 
B, Marks W, Witte L, Wu Y, Hicklin D, Zhu ZP, Hackett NR, Crystal RG, Moore 
MAS, Hajjar KA, Manova K, Benezra R, Rafii S: Impaired recruitment of 
Received: 20 April 2010 Accepted: 22 June 2010 
Published: 22 June 2010
This article is available from: http://www.jangiogenesis.com/content/2/1/10 © 2010 Medinger and Mross; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Angiogenesis Research 2010, 2:10Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
http://www.jangiogenesis.com/content/2/1/10
Page 9 of 11
bone-marrow derived endothelial and hematopoietic precursor cells 
blocks tumor angiogenesis and growth.  Nat Med 2001, 7:1194-1201.
4. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors.  
Nat Med 2003, 9:669-676.
5. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, 
Ferrara N: Analysis of biological effects and signaling properties of Flt-1 
(VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-
specific vascular endothelial growth factor mutants.  J Biol Chem 2001, 
276:3222-3230.
6. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu 
Z, Witte L, Crystal RG, Moore MA, Rafii S: Vascular endothelial growth 
factor and angiopoietin-1 stimulate postnatal hematopoiesis by 
recruitment of vasculogenic and hematopoietic stem cells.  J Exp Med 
2001, 193:1005-1014.
7. Bellamy WT, Richter L, Frutiger Y, Grogan TM: Expression of vascular 
endothelial growth factor and its receptors in hematopoietic 
malignancies.  Cancer Res 1999, 59:728-733.
8. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel 
H, Rafii S: Vascular trauma induces rapid but transient mobilization of 
VEGFR2(+)AC133(+) endothelial precursor cells.  Circ Res 2001, 
88:167-174.
9. Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, 
Petrucci E, Pelosi E, Morsilli O, Gabbianelli M, Testa U, Peschle C: 
Autocrine-paracrine VEGF loops potentiate the maturation of 
megakaryocytic precursors through Flt1 receptor.  Blood 2003, 
101:1316-1323.
10. Thurston G, Noguera-Troise I, Yancopoulos GD: The delta paradox: DLL4 
blockade leads to more tumour vessels but less tumour growth.  Nat 
Rev Cancer 2007, 7:327-331.
11. Yan M, Plowman GD: Delta-like 4/Notch signaling and its therapeutic 
implications.  Clin Cancer Res 2007, 13:7243-7246.
12. Diez H, Fischer A, Winkler A, Hu CJ, Hatzopoulos AK, Breier G, Gessler M: 
Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in 
endothelial progenitor cells and adoption of arterial cell fate.  Exp Cell 
Res 2007, 313:1-9.
13. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, 
Lin HC, Yancopoulos GD, Thurston G: Blockade of Dll4 inhibits tumour 
growth by promoting non-productive angiogenesis.  Nature 2006, 
444:1032-1037.
14. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, 
Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de 
Sauvage F, Plowman G, Yan M: Inhibition of Dll4 signalling inhibits 
tumour growth by deregulating angiogenesis.  Nature 2006, 
444:1083-1087.
15. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley 
H, Heikamp E, Hainfellner JA, Harris AL: Delta-like 4 Notch ligand 
regulates tumor angiogenesis, improves tumor vascular function, and 
promotes tumor growth in vivo.  Cancer Res 2007, 67:11244-11253.
16. Aguayo A: The role of angiogenesis in the biology and therapy of 
myelodysplastic syndromes.  Curr Hematol Rep 2004, 3:184-191.
17. Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, 
Dirnhofer S, Tichelli A, Tzankov A: Angiogenesis and vascular endothelial 
growth factor-/receptor expression in myeloproliferative neoplasms: 
correlation with clinical parameters and JAK2-V617F mutational status.  
Br J Haematol 2009, 146:150-157.
18. Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, Büchner T, Berdel 
WE, Mesters RM: Increased angiogenesis in the bone marrow of 
patients with acute myeloid leukemia.  Blood 2000, 95:2637-2644.
19. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, 
Lambertenghi-Deliliers G, Pezzella F: Angiogenesis in myelodysplastic 
syndromes.  Br J Cancer 1999, 81:1398-1401.
20. Tzankov A, Heiss S, Ebner S, Sterlacci W, Schaefer G, Augustin F, Fiegl M, 
Dirnhofer S: Angiogenesis in nodal B cell lymphomas: a high 
throughput study.  J Clin Pathol 2007, 60:476-482.
21. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F: 
Bone marrow angiogenesis and progression in multiple myeloma.  Br J 
Haematol 1994, 87:503-508.
22. Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling UM, 
Schuch G, Hossfeld DK, Fiedler W: Analysis of concerted expression of 
angiogenic growth factors in acute myeloid leukemia: expression of 
angiopoietin-2 represents an independent prognostic factor for 
overall survival.  J Clin Oncol 2005, 23:1109-1117.
23. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, 
Bussolino F, Dammacco F: Bone marrow neovascularization, plasma cell 
angiogenic potential, and matrix metalloproteinase2 secretion parallel 
progression of human multiple myeloma.  Blood 1999, 93:30643073.
24. Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, 
Kowalska MA, Gewirtz AM, Emerson SG, Ratajczak MZ: Numerous growth 
factors, cytokines, and chemokines are secreted by human CD34(+) 
cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate 
normal hematopoiesis in an autocrine/paracrine manner.  Blood 2001, 
97:3075-3085.
25. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular 
endothelial growth factor is a secreted angiogenic mitogen.  Science 
1989, 246:1306-1309.
26. Fiedler W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M, Hossfeld 
DK: Vascular endothelial growth factor, a possible paracrine growth 
factor in human acute myeloid leukemia.  Blood 1997, 89:1870-1875.
27. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W: Autocrine stimulation 
of VEGFR-2 activates human leukemic cell growth and migration.  J Clin 
Invest 2000, 106:511-521.
28. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M: Cellular 
vascular endothelial growth factor is a predictor of outcome in 
patients with acute myeloid leukemia.  Blood 1999, 94:3717-3721.
29. Borggrefe T, Oswald F: The Notch signaling pathway: transcriptional 
regulation at Notch target genes.  Cell Mol Life Sci 2009, 66:1631-1646.
30. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, 
Blacklow SC, Look AT, Aster JC: Activating mutations of NOTCH1 in 
human T cell acute lymphoblastic leukemia.  Science 2004, 306:269-271.
31. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B: 
Activated Notch1 signaling promotes tumor cell proliferation and 
survival in Hodgkin and anaplastic large cell lymphoma.  Blood 2002, 
99:3398-3403.
32. Jundt F, Acikgöz O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B, 
Mathas S, Hummel M, Stein H, Reichardt HM, Dörken B: Aberrant 
expression of Notch1 interferes with the B-lymphoid phenotype of 
neoplastic B cells in classical Hodgkin lymphoma.  Leukemia 2008, 
22:1587-1594.
33. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke 
M, Berger R: Notch2 is involved in the overexpression of CD23 in B-cell 
chronic lymphocytic leukemia.  Blood 2002, 99:3742-3747.
34. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth M, Hubmann 
R: Induction of apoptosis by proteasome inhibitors in B-CLL cells is 
associated with downregulation of CD23 and inactivation of Notch2.  
Leukemia 2005, 19:260-267.
35. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli 
A, Coaccioli S, Screpanti I, Marconi P: Constitutively activated Notch 
signaling is involved in survival and apoptosis resistance of B-CLL cells.  
Blood 2009, 113:856-865.
36. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI: Involvement of 
Notch-1 signaling in bone marrow stroma-mediated de novo drug 
resistance of myeloma and other malignant lymphoid cell lines.  Blood 
2004, 103:3503-3510.
37. Jundt F, Pröbsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, 
Mathas S, Bargou RC, Manz R, Stein H, Dörken B: Jagged1-induced Notch 
signaling drives proliferation of multiple myeloma cells.  Blood 2004, 
103:3511-3515.
38. Vacca A, Dammacco F, Richardson PG, Anderson KC: Bortezomib 
mediates antiangiogenesis in multiple myeloma via direct and indirect 
effects on endothelial cells.  Cancer Res 2006, 66:184-191.
39. Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, 
Possinger K: Bone marrow microvessel density is a prognostic factor for 
survival in patients with multiple myeloma.  Ann Hematol 2000, 
79:574-577.
40. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust 
JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR: Prognostic value of bone 
marrow angiogenesis in multiple myeloma.  Clin Cancer Res 2000, 
6:3111-3116.
41. Munshi NC, Wilson C: Increased bone marrow microvessel density in 
newly diagnosed multiple myeloma carries a poor prognosis.  Semin 
Oncol 2001, 28:565-569.
42. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, 
Rajkumar SV: Expression of VEGF and its receptors by myeloma cells.  
Leukemia 2003, 17:2025-2031.Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
http://www.jangiogenesis.com/content/2/1/10
Page 10 of 11
43. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta 
D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC: 
Vascular endothelial growth factor triggers signaling cascades 
mediating multiple myeloma cell growth and migration.  Blood 2001, 
98:428-435.
44. Podar K, Anderson KC: The pathophysiological role of VEGF in 
hematological malignancies: Therapeutic implications.  Blood 2005, 
105:138395.
45. Rajkumar SV, Mesa RA, Tefferi A: A review of angiogenesis and anti-
angiogenic therapy in hematologic malignancies.  J Hematother Stem 
Cell Res 2002, 11:33-47.
46. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, Greipp PR, 
Rajkumar SV: Bone marrow angiogenic ability and expression of 
angiogenic cytokines in myeloma: evidence favoring loss of marrow 
angiogenesisinhibitory activity with disease progression.  Blood 2004, 
104:1159-1165.
47. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J: 
Spectrum of tumor angiogenesis in the bone marrow of children with 
acute lymphoblastic leukemia.  Am J Pathol 1997, 150:815-821.
48. Yetgin S, Yenicesu I, Cetin M, Tuncer M: Clinical importance of serum 
vascular endothelial and basic fibroblast growth factors in children 
with acute lymphoblastic leukemia.  Leuk Lymphoma 2001, 42:83-88.
49. Hanahan D, Folkman J: Patterns and emerging mechanisms of the 
angiogenic switch during tumorigenesis.  Cell 1996, 86:353-364.
50. Dong X, Han ZC, Yang R: Angiogenesis and antiangiogenic therapy in 
hematologic malignancies.  Crit Rev Oncol/Hematol 2007, 62:105-118.
51. Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC: 
Dysregulated angiogenesis in B-chronic lymphocytic leukemia: 
morphologic, immunohistochemical, and flow cytometric evidence.  
Diagn Pathol 2008, 3:16.
52. Norén-Nyström U, Heyman M, Frisk P, Golovleva I, Sundström C, Porwit A, 
Roos G, Bergh A, Forestier E: Vascular density in childhood acute 
lymphoblastic leukaemia correlates to biological factors and outcome.  
Br J Haematol 2009, 146:521-350.
53. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T: 
Plasma vascular endothelial growth factor levels have prognostic 
significance in patients with acute myeloid leukemia but not in 
patients with myelodysplastic syndromes.  Cancer 2002, 95:1923-1930.
54. Hou HA, Ting-Fang Shih T, Liu CY, Chen BB, Tang JL, Yao M, Huang SY, 
Chou WC, Hsu CY, Tien HF: Changes in MR bone marrow angiogenesis 
on day 7 after induction chemotherapy can predict outcome of acute 
myeloid leukemia.  Haematologica 2010 in press.
55. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J: Bone 
marrow in polycythemia vera, chronic myelocytic leukemia, and 
myelofibrosis has an increased vascularity.  Am J Pathol 2000, 157:15-19.
56. Wrobel T, Mazur G, Surowiak P, Wolowiec D, Jelen M, Kuliczkowsky K: 
Increased expression of vascular endothelial growth factor (VEGF) in 
bone marrow of patients with myeloproliferative disorders (MPD).  
Pathol Oncol Res 2003, 9:170-173.
57. Gianelli U, Vener C, Raviele PR, Savi F, Somalvico F, Calori R, Iurlo A, Radaelli 
F, Fermo E, Bucciarelli P, Bori S, Coggi G, Deliliers GL: VEGF expression 
correlates with microvessel density in Philadelphia chromosome-
negative chronic myeloproliferative disorders.  Am J Clin Pathol 2007, 
128:966-973.
58. Ponzoni M, Savage DG, Ferreri AJ, Pruneri G, Viale G, Servida P, Bertolini F, 
Orazi A: Chronic idiopathic myelofibrosis: independent prognostic 
importance of bone marrow microvascular density evaluated by 
CD105 (endoglin) immunostaining.  Mod Pathol 2004, 17:1513-1520.
59. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, 
Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in 
myeloproliferative isorders.  N Engl J Med 2005, 352:1779-1790.
60. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC: 
Acquisition of the V617F mutation of JAK2 is a late genetic event in a 
subset of patients with myeloproliferative disorders.  Blood 2006, 
108:1377-1380.
61. Alonci A, Allegra A, Bellomo G, Penna G, D'Angelo A, Quartarone E, 
Musolino C: Evaluation of circulating endothelial cells, VEGF and 
VEGFR2 serum levels in patients with chronic myeloproliferative 
diseases.  Hematol Oncol 2008, 26:235-239.
62. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim 
W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross 
R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic colorectal cancer.  N Engl J Med 2004, 
350:2335-2342.
63. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, 
Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-
small-cell lung cancer.  N Engl J Med 2006, 355:2542-2550.
64. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, 
Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel 
alone for metastatic breast cancer.  N Engl J Med 2007, 357:2666-2676.
65. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, 
Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, 
Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study 
Group: Sorafenib in advanced clear-cell renal-cell carcinoma.  N Engl J 
Med 2007, 356:125-134.
66. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, 
Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin 
RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.  
N Engl J Med 2007, 356:115-124.
67. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, 
Winkler M, Ferrara N: Humanization of an anti-vascular endothelial 
growth factor monoclonal antibody for the therapy of solid tumors 
and other disorders.  Cancer Res 1997, 57:4593-4599.
68. Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C, 
Zühlsdorf M, Berdel WE, Mesters RM: Bevacizumab reduces VEGF 
expression in patients with relapsed and refractory acute myeloid 
leukemia without clinical antileukemic activity.  Leukemia 2007, 
21:1310-1312.
69. Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, 
Chen H, Zwiebel J: Targeting vascular endothelial growth factor for 
relapsed and refractory adult acute myelogenous leukemias: therapy 
with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and 
bevacizumab.  Clin Cancer Res 2004, 10:3577-3585.
70. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, 
Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, 
Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE: A phase 2 clinical 
study of SU5416 in patients with refractory acute myeloid leukemia.  
Blood 2003, 102:2763-2767.
71. Mesters RM, Padró T, Bieker R, Steins M, Kreuter M, Göner M, Kelsey S, 
Scigalla P, Fiedler W, Büchner T, Berdel WE: Stable remission after 
administration of the receptor tyrosine kinase inhibitor SU5416 in a 
patient with refractory acute myeloid leukemia.  Blood 2001, 
98:241-243.
72. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, 
Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, 
Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE: SU5416, a 
small molecule tyrosine kinase receptor inhibitor, has biologic activity 
in patients with refractory acute myeloid leukemia or myelodysplastic 
syndromes.  Blood 2003, 102:795-801.
73. Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, 
Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marmé D: 
PTK787/ZK 22 a specific vascular endothelial growth factor-receptor 
tyrosine kinase inhibitor, affects the anatomy of the tumor vascular 
bed and the functional vascular properties as detected by dynamic 
enhanced magnetic resonance imaging.  Cancer Res 2584, 
62:4015-4022.
74. Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, 
Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C: Phase I 
clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF 
receptor inhibitor, in patients with liver metastases from solid tumors.  
Eur J Cancer 2005, 41:1291-1299.
75. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, 
Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer 
A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner 
M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F: 
PTK787/ZK 22 a novel and potent inhibitor of vascular endothelial 
growth factor receptor tyrosine kinases impairs vascular endothelial 
growth factor-induced responses and tumor growth after oral 
administration.  Cancer Res 2584, 60:2178-2189.
76. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, 
Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood 
J, Munshi NC, Anderson KC: The vascular endothelial growth factor 
receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth Medinger and Mross Journal of Angiogenesis Research 2010, 2:10
http://www.jangiogenesis.com/content/2/1/10
Page 11 of 11
and migration of multiple myeloma cells in the bone marrow 
microenvironment.  Cancer Res 2002, 62:5019-5026.
77. Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, 
Rosamilia M, Schuster MW, Laurent D, Feldman EJ: Phase 1 study of 
PTK787/ZK 22 a small molecule tyrosine kinase receptor inhibitor, for 
the treatment of acute myeloid leukemia and myelodysplastic 
syndrome.  Leukemia 2584, 20:952-957.
78. Barbarroja N, Torres LA, Luque MJ, Carretero RM, Valverde-Estepa A, Lopez-
Sanchez LM, Rodriguez-Ariza A, Velasco F, Torres A, López-Pedrera C: 
Additive effect of PTK787/ZK 22 a potent inhibitor of VEGFR 
phosphorylation, with Idarubicin in the treatment of acute myeloid 
leukemia.  Exp Hematol 2584, 37:679-691.
79. Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques 
C, Laurent D, Albitar M, Feldman EJ, Roboz GJ: PTK787/ZK 22 a small 
molecule tyrosine kinase receptor inhibitor of vascular endothelial 
growth factor (VEGF), has modest activity in myelofibrosis with 
myeloid metaplasia.  Leuk Res 2584, 31:891-897.
80. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, 
Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey 
SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley 
AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ: AZD2171: a 
highly potent, orally bioavailable, vascular endothelial growth factor 
receptor-2 tyrosine kinase inhibitor for the treatment of cancer.  Cancer 
Res 2005, 65:4389-4400.
81. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, 
Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, 
Unger C: Phase I clinical study of AZD an oral vascular endothelial 
growth factor signaling inhibitor, in patients with advanced solid 
tumors.  J Clin Oncol 2171, 20:3045-3054.
82. Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, Zirrgiebel U, 
Robertson JD, Puchalski TA, Collins B, Jürgensmeier JM, Serve H: An open-
label, phase I study of cediranib (RECENTIN) in patients with acute 
myeloid leukemia.  Leuk Res 2010, 34:196-202.
83. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, 
Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor 
activity of thalidomide in refractory multiple myeloma.  N Engl J Med 
1999, 341:1565-1571.
84. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, 
Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G: 
Extended survival in advanced and refractory multiple myeloma after 
single-agent thalidomide: identification of prognostic factors in a 
phase 2 study of 169 patients.  Blood 2001, 98:492-494.
85. Moncada B, Baranda ML, González-Amaro R, Urbina R, Loredo CE: 
Thalidomide-effect on T cell subsets as a possible mechanism of 
action.  Int J Lepr Other Mycobact Dis 1985, 53:201-205.
86. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an 
inhibitor of angiogenesis.  Proc Natl Acad Sci USA 1994, 91:4082-4085.
87. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, 
Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, 
Payvandi F, Muller G, Stirling DI, Anderson KC: Adherence of multiple 
myeloma cells to bone marrow stromal cells upregulates vascular 
endothelial growth factor secretion: therapeutic applications.  
Leukemia 2001, 15:1950-1961.
88. Teo SK: Properties of thalidomide and its analogues: implications for 
anticancer therapy.  AAPS J 2005, 7:E14-19.
89. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, 
Stirling D, Dalgleish AG: Novel thalidomide analogues display anti-
angiogenic activity independently of immunomodulatory effects.  Br J 
Cancer 2002, 87:1166-1172.
90. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR: Phase III clinical 
trial of thalidomide plus dexamethasone compared with 
dexamethasone alone in newly diagnosed multiple myeloma: a clinical 
trial coordinated by the Eastern Cooperative Oncology Group.  J Clin 
Oncol 2006, 24:431-436.
91. Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M: Single agent 
thalidomide in patients with relapsed or refractory acute myeloid 
leukaemia.  Br J Haematol 2003, 123:436-441.
92. Steins MB, Padró T, Bieker R, Ruiz S, Kropff M, Kienast J, Kessler T, Buechner 
T, Berdel WE, Mesters RM: Efficacy and safety of thalidomide in patients 
with acute myeloid leukemia.  Blood 2002, 99:834-839.
93. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N: Combination of 5-
azacytidine and thalidomide for the treatment of myelodysplastic 
syndromes and acute myeloid leukemia.  Cancer 2008, 113:1596-1604.
94. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien 
SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM: 
Thalidomide therapy for myelofibrosis with myeloid metaplasia.  
Cancer 2006, 106:1974-1984.
95. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A: Mechanism of 
action of lenalidomide in hematological malignancies.  J Hematol Oncol 
2009, 2:36.
96. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, 
Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak 
Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD: Lenalidomide plus 
dexamethasone for relapsed or refractory multiple myeloma.  N Engl J 
Med 2007, 357:2123-2132.
97. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel 
D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, 
Olesnyckyj M, Zeldis JB, Knight RD: Lenalidomide plus dexamethasone 
for relapsed multiple myeloma in North America.  N Engl J Med 2007, 
357:2133-2142.
98. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, 
Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, 
Giles F, Kantarjian HM: Lenalidomide therapy in myelofibrosis with 
myeloid metaplasia.  Blood 2006, 108:1158-1164.
99. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, 
Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S: 
Lenalidomide plus prednisone results in durable clinical, 
histopathologic, and molecular responses in patients with 
myelofibrosis.  J Clin Oncol 2009, 27:4760-4766.
100. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, 
Elliott P, Van Waes C: Novel proteasome inhibitor PS-341 inhibits 
activation of nuclear factor-kappa B, cell survival, tumor growth, and 
angiogenesis in squamous cell carcinoma.  Clin Cancer Res 2001, 
7:1419-1428.
101. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, 
Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC: 
Bortezomib mediates antiangiogenesis in multiple myeloma via direct 
and indirect effects on endothelial cells.  Cancer Research 2006, 
66:184-191.
102. Kane RC, Farrell AT, Sridhara R, Pazdur R: United States Food and Drug 
Administration approval summary: bortezomib for the treatment of 
progressive multiple myeloma after one prior therapy.  Clinical Cancer 
Research 2006, 12:2955-2960.
103. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, 
Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, 
Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, 
Cakana A, van de Velde H, San Miguel JF: Bortezomib Plus Melphalan 
and Prednisone Compared With Melphalan and Prednisone in 
Previously Untreated Multiple Myeloma: Updated Follow-Up and 
Impact of Subsequent Therapy in the Phase III VISTA Trial.  J Clin Oncol 
2010, 28:2259-2266.
104. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, 
Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, 
Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, 
Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson 
KC: Lenalidomide, bortezomib, and dexamethasone combination 
therapy in patients with newly diagnosed multiple myeloma.  Blood 
2010 in press.
105. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, 
Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, 
Schenkein D, Neuberg D, Stone RM, Amrein PC: Phase I and 
pharmacokinetic study of bortezomib in combination with idarubicin 
and cytarabine in patients with acute myelogenous leukemia.  Clin 
Cancer Res 2008, 14:1446-1454.
doi: 10.1186/2040-2384-2-10
Cite this article as: Medinger and Mross, Clinical trials with anti-angiogenic 
agents in hematological malignancies Journal of Angiogenesis Research 2010, 
2:10